摘要
目的:评价癌康宁合剂对晚期非小细胞肺癌(NSCLC)患者生活质量和生存期的影响。方法:将174例NSCLC患者随机分为对照组和观察组。对照组采用TP方案+姑息治疗的综合措施。观察组在对照组的基础上给予癌康宁合剂,30 mL/次,3次/天,口服,维持治疗。疗程12个月,或到达终点事件(死亡)。记录生存期和6个月和一年的生存率;在治疗前和治疗后3个月进行肺癌生活质量量表(FACT-L 4.0)评分,检测T淋巴细胞亚群(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)、自然杀伤细胞(NK)、癌胚抗原(CEA)、糖抗原125(CA125)、细胞角蛋白19片段21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)和神经元特异性烯醇化酶(NSE)、Th1细胞因子[白介素-2(IL-2)、干扰素-γ(IFN-γ)]、Th2细胞因子(IL-4、IL-6、IL-10)水平。结果:观察组6个月生存率为75.31%,显著高于对照组的58.23%(P<0.05);观察组一年生存率为46.91%,高于对照组的30.38%(P<0.05);观察组生存期为16个月(95%CI:4.52~23.61),显著长于对照组的10个月(95%CI:4.47~19.75)(P<0.05);观察组FACT-L各维度和总分均显著高于对照组(P<0.05);观察组NK、CD3^+、CD4^+、CD4^+/CD8^+水平显著高于对照组,CD8^+显著低于对照组(P<0.05);观察组IL-2、IFN-γ水平显著高于对照组,IL-4、IL-6、IL-10水平低于对照组(P<0.05);观察组CEA、CA125、CYFRA21-1、SCC-Ag、NSE水平显著低于对照组(P<0.05)。结论:癌康宁合剂辅助用于晚期NSCLC化疗患者维持治疗,可延长患者的生存期和提高生存率,改善生活质量,调整Th1/Th2平衡,增强免疫功能,抑制肿瘤标志物的表达,对改善NSCLC患者预后具有积极的意义。
Objective:To evaluate the effects of Aikangning mixture on quality of life and survival period of advanced non-small cell lung cancer(NSCLC)patients.Methods:174 NSCLC patients were randomly divided into control group and observation group.The control group was treated with TP method and palliative treatment.The observation group was given a mixture of Aikangning for maintenance therapy on the basis of the control group,30 mL/time,3 times/d,oral administration.The course of treatment was 12 months or at the ending of life.Survival period,survival rates of six months and one year were recorded.Before treatment and at the third month after treatment,scores of lung cancer quality of life scale(FACT-L 4.0)were graded,the levels of T lymphocyte subsets(CD3^+,CD4^+,CD8^+,CD4^+/CD8^+),natural killer cells(NK),carcinoembryonic antigen(CEA),carbohydrate antigens 125(CA125),cytokeratin 19 fragment 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC-Ag),neuron-specific enolase(NSE),Th1 cell factor(IL-2,IFN-γ),Th2 cell factor(IL-4,IL-6 and IL-10)were detected.Results:The survival rate in observation group was 75.31%during 6 months,significantly higher than that in control group(58.23%)(P<0.05),the survival rate in observation group was 46.91%during 1 year,higher than that in control group(30.38%)(P<0.05).The survival period in observation group was 16 months(95%CI:4.52~23.61),significantly longer than 10 month in control group(95%CI:4.47~19.75)(P<0.05).The FACT-L dimension and the total score in observation group were significantly higher than those in control group(P<0.05).The levels of NK,CD3^+,CD4^+and CD4^+/CD8^+were significantly higher than those in control group,and CD8^+level was significantly lower than that in control group(P<0.05).And levels of IL-2 and IFN-γin observation group were significantly higher than those in control group and the levels of IL-4,IL-6,IL-10,CEA,CA125,CYFRA21-1,SCC-Ag,NSE in observation group were significantly lower than those in control group(P<0.01).Conclusion:Aikangning mixture is adjuvant for maintenance treatment of advanced NSCLC chemotherapy patients,can prolong the survival time and improve the survival rate,improve the quality of life,adjust the balance of Th1/Th2,enhance the immune function and inhibit the expression of tumor markers,and has positive significance for the prognosis of NSCLC patients.
作者
付玲
张琼
刘勇
陶劲
罗玲
FU Ling;ZHANG Qiong;LIU Yong;TAO Jin;LUO Ling(Chongqing Traditional Chinese Medicine Hospital,Chongqing 400020,China)
出处
《中药材》
CAS
北大核心
2019年第11期2696-2700,共5页
Journal of Chinese Medicinal Materials
基金
国家中医药现代化研究重点专项(2018YFC1704100)
国家重点研发计划(2018YFC1704104)
